U.S. influenza vaccines for 2012–13 will contain A/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage) antigens.
The influenza A(H3N2) and B antigens differ from the respective 2010–11 and 2011–12 seasonal vaccine antigens (3).
The influenza A(H1N1) vaccine virus strain is derived from an influenza A(H1N1)pdm09 (2009[H1N1]) virus and was included in the 2009(H1N1) monovalent pandemic vaccine as well as the 2010–11 and 2011–12 seasonal vaccines.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm
Also, this [A copy of the minutes of the meeting to approve the above vaccines:
Food and Drug Administration
Center for Biologics Evaluation and Review
SUMMARY MINUTES
VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE
February 28-29, 2012
These summary minutes for the February 28-29, 2012 Meeting of the Vaccines and Related Biological Products Advisory Committee were approved on March 13, 2012.
I certify that I participated in the February 28-29, 2012 Meeting of the Vaccines and Related Biological Products Advisory Committee and that these minutes accurately reflect what transpired.
From the pdf file:
Full document is located here: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm296193.pdf
No comments:
Post a Comment